Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
United States
781 674 4400
https://www.agenusbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 389
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Garo H. Armen Ph.D. | Founder, Executive Chairman & CEO | 1.34M | 無 | 1953 |
| Ms. Christine M. Klaskin | VP of Finance, Principal Financial Officer & Principal Accounting Officer | 407.44k | 無 | 1966 |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer | 970.98k | 無 | 1961 |
| Craig Winter | Chief Information Officer | 無 | 無 | 無 |
| Mr. Zack Armen | Head of Investor Relations | 無 | 無 | 無 |
| Ms. Tracy Mazza Clemente | Chief People Officer | 無 | 無 | 無 |
| Mr. Alfred Dadson | Chief Manufacturing Officer | 無 | 無 | 無 |
| Mr. Eric Humes | Chief Quality Officer | 無 | 無 | 無 |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board & Chief Strategic Advisor | 無 | 無 | 無 |
| Dr. Robin G. Taylor M.B.A., Ph.D. | Chief Commercial Officer | 無 | 無 | 無 |
描述
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
公司管治
截至 2024年5月1日 止，Agenus Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：5；董事會：6；股東權利：8；現金賠償：7。
